Grandfield & Dodd LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Grandfield & Dodd LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,205 shares of the biopharmaceutical company’s stock after buying an additional 1,998 shares during the quarter. Grandfield & Dodd LLC’s holdings in Regeneron Pharmaceuticals were worth $18,483,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Colonial Trust Advisors bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Finally, SouthState Corp increased its stake in shares of Regeneron Pharmaceuticals by 550.0% during the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on REGN shares. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 29th. Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target for the company. Finally, Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $789.91.

Regeneron Pharmaceuticals Trading Up 1.9%

Regeneron Pharmaceuticals stock opened at $694.99 on Friday. The company has a market capitalization of $73.04 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $803.41. The stock has a 50-day moving average price of $596.36 and a 200 day moving average price of $570.46. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $12.46 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.